Famotidine is not considered harmful to the liver for the vast majority of people who take it. The drug is rated a “C” on the LiverTox likelihood scale, meaning it is a probable but rare cause of clinically apparent liver injury. Minor bumps in liver enzyme levels occur in 1% to 4% of people on long-term famotidine, but people taking a placebo show the same rates, suggesting the drug itself isn’t the cause.
How Famotidine Moves Through Your Body
One reason famotidine is easy on the liver is that it mostly bypasses it. About 65% to 70% of a dose leaves your body through the kidneys, excreted as the unchanged drug. Only 25% to 30% is processed by the liver. This minimal liver involvement means the organ simply doesn’t handle much of the workload when you take famotidine, which lowers the chance of liver-related side effects compared to drugs that are heavily metabolized there.
Famotidine also does not significantly interfere with the liver’s enzyme systems that break down other medications. This is a notable advantage over cimetidine, an older drug in the same class, which is well known for blocking those enzymes and causing drug interactions.
What the Liver Injury Cases Actually Look Like
Serious liver injury from famotidine has been reported, but the number of published cases is extremely small. The pattern in those rare cases has typically been hepatocellular, meaning the injury affects the liver cells themselves rather than the bile ducts. Onset ranges from 1 to 14 weeks after starting the drug.
In the handful of documented cases, patients were taking 40 mg daily. One person developed jaundice within a week and required hospitalization but recovered in about five weeks. Another case involved a patient also taking cimetidine, making it hard to pin the injury on famotidine alone; that patient recovered in roughly six weeks. When liver tissue has been examined in similar cases, it shows localized cell death with inflammation and mild bile backup, a pattern consistent with an unpredictable, immune-type reaction rather than direct toxicity from the drug.
The FDA’s current prescribing label, updated in July 2024, lists cholestatic jaundice and hepatitis as postmarketing adverse reactions. Elevated liver enzymes are listed as a clinical trial finding occurring in fewer than 1% of patients. These are standard disclosures for a drug with decades of widespread use and a very small signal.
Famotidine vs. PPIs for People With Liver Disease
If you already have liver disease, the comparison between famotidine and proton pump inhibitors (PPIs) like omeprazole is worth understanding. A study of veterans with decompensated cirrhosis (advanced liver disease with complications) found that PPI users developed serious infections at 1.66 times the rate of non-users. For infections specifically tied to acid suppression, the rate was 1.75 times higher.
H2 blockers like famotidine did not show the same risk. Researchers found no association between H2 blocker use and acid-suppression-related infections in people with advanced cirrhosis. The study’s authors went so far as to suggest that clinicians should re-evaluate PPI prescriptions in cirrhosis patients and replace them with H2 blockers where possible. The sample size for the H2 blocker group was smaller, so the finding isn’t definitive, but the contrast with PPIs was clear.
Dosing With Existing Liver Problems
If you have cirrhosis or chronic liver disease, you might expect clear dosing guidelines for famotidine. In practice, they don’t exist in a useful form. A systematic review of dose recommendations for common drugs in liver cirrhosis classified famotidine’s guidance as “nonspecific,” meaning the available recommendations amounted to vague advice like “use with precaution” or “start low” rather than concrete adjusted doses. This reflects both the drug’s relatively low liver burden and the limited data on its behavior in advanced liver disease.
Because famotidine is primarily cleared by the kidneys rather than the liver, impaired liver function alone doesn’t dramatically change how the drug is processed. Kidney function matters more for famotidine dosing than liver function does.
Signs to Watch For
The rare liver reactions tied to famotidine tend to show up within the first few months of use. Yellowing of the skin or eyes, unusually dark urine, persistent nausea, or upper-right abdominal pain are the hallmarks of drug-induced liver injury regardless of the cause. These symptoms developed in the documented famotidine cases and resolved within five to six weeks after stopping the drug.
For most people taking famotidine for heartburn or acid reflux, the liver risk is negligible. The drug has been available since the 1980s, used by millions of people, and the total number of published liver injury cases remains in the single digits. Among common acid-reducing medications, famotidine carries one of the more favorable liver safety profiles.